TGFβ is a major driver of glioma progression.5 6 To inhibit TGFβ, we decided to use HSC gene therapy to deliver soluble TGFβ decoy receptor fused to the fragment crystallisable IgG (Fc) region (sTGFβRIIFc)20 to intracranial GL261 tumors. Here, TGFB1 is linked to glioma.